Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454971 | 0.89 | KDM4E (0.67) | HRH3MAPTKDM4EGAALMNA | |
| SCHEMBL5458846 | 0.86 | HRH3 (0.74) | HRH3HTR6KDM4EGAADRD3 | |
| SCHEMBL5458302 | 0.85 | PKM (0.58) | HRH3MAPTKDM4EGAALMNA | |
| SCHEMBL5468173 | 0.85 | HRH3 (0.59) | HRH3HTR6LMNAMAPK1DRD3 | |
| SCHEMBL5459752 | 0.83 | HRH3 (0.62) | HRH3HTR6KDM4EGAALMNA | |
| SCHEMBL5453457 | 0.83 | HRH3 (0.59) | HRH3HTR6KDM4ELMNATSHR | |
| SCHEMBL5472482 | 0.83 | HTT (0.59) | HRH3HTR6MAPTKDM4EGAA | |
| SCHEMBL5472280 | 0.82 | HRH3 (0.59) | HRH3HTR6KDM4EGAAMAPK1 | |
| SCHEMBL5462288 | 0.82 | HRH3 (0.59) | HRH3HTR6KDM4EGAAMAPK1 | |
| SCHEMBL5458190 | 0.81 | HRH3 (0.55) | HRH3HTR6KDM4EMAPK1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885HTR6 373/4885MAPT 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.